|
|
||||||||
Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK
(Correspondence should be addressed to C A McArdle; Email: craig.mcardle{at}bris.ac.uk)
In heterologous expression systems, human GnRH receptors (hGnRHRs) are poorly expressed at the cell surface and this may reflect inefficient exit from the endoplasmic reticulum. Here, we have defined the proportion of GnRHRs at the cell surface using a novel assay based on adenoviral transduction with epitope-tagged GnRHRs followed by staining and semi-automated imaging. We find that in MCF7 (breast cancer) cells, the proportional cell surface expression (PCSE) of hGnRHRs is remarkably low (<1%), when compared with Xenopus laevis (X) GnRHRs (
40%). This distinction is retained at comparable whole cell expression levels, and the hGnRHR PCSE is increased by addition of the XGnRHR C-tail (h.XGnRHR) or by a membrane-permeant pharmacological chaperone (IN3). The IN3 effect is concentration- and time-dependent and IN3 also enhances the hGnRHR-mediated (but not h.XGnRHR- or mouse GnRHR-mediated) stimulation of [3H]inositol phosphate accumulation and the hGnRHR-mediated reduction in cell number. We also find that the PCSE for hGnRHRs and h.XGnRHRs is low and is greatly increased by IN3 in two hormone-dependent cancer lines, but is higher and less sensitive to IN3 in a gonadotrope line. Finally, we show that the effect of IN3 on hGnRHR PCSE is not mimicked or blocked by two peptide antagonists although they do increase the PCSE for h.XGnRHRs, revealing that an antagonist-occupied cell surface GnRHR conformation can differ from that of the unoccupied receptor. The low PCSE of hGnRHRs and this novel peptide antagonist effect may be important for understanding GnRHR function in extrapituitary sites.
This article has been cited by other articles:
![]() |
A. R. Finch, C. J. Caunt, S. P. Armstrong, and C. A. McArdle Plasma Membrane Expression of Gonadotropin-Releasing Hormone Receptors: Regulation by Peptide and Nonpeptide Antagonists Mol. Endocrinol., February 1, 2010; 24(2): 423 - 435. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Thomas High-Content Screening: A Decade of Evolution J Biomol Screen, January 1, 2010; 15(1): 1 - 9. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Armstrong, C. J. Caunt, R. C. Fowkes, K. Tsaneva-Atanasova, and C. A. McArdle Pulsatile and Sustained Gonadotropin-releasing Hormone (GnRH) Receptor Signaling: DOES THE Ca2+/NFAT SIGNALING PATHWAY DECODE GnRH PULSE FREQUENCY? J. Biol. Chem., December 18, 2009; 284(51): 35746 - 35757. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G J Hazell, S. T Yao, J. A Roper, E. R Prossnitz, A.-M. O'Carroll, and S. J Lolait Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues J. Endocrinol., August 1, 2009; 202(2): 223 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Finch, C. J. Caunt, S. P. Armstrong, and C. A. McArdle Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors Am J Physiol Cell Physiol, January 1, 2009; 297(3): C591 - C600. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |